Beranda › Leukemia Limfoblastik Akut › Illinois
Uji klinis Leukemia Limfoblastik Akut di Illinois
20 studi untuk Leukemia Limfoblastik Akut mencari peserta di lokasi di Illinois.
Kota di Illinois
Teks studi resmi (Bahasa Inggris)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- dan 54 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- The University of Chicago Medical Center, Chicago
Menerima pesertaFase 1/2
30 Days · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04065399The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- dan 6 lainnya
Menerima pesertaFase 1/2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaFase 2
Usia 7 hingga 25 · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT05082519A Study of CTD402 in T-ALL/LBL Patients
- University of Chicago, Chicago
Menerima pesertaFase 1/2
Usia 1 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07070219Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- The University of Chicago, Chicago
Menerima pesertaStudi observasional
1 Day – 17 Years · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT06274788Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Decatur
Menerima pesertaFase 1/2
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT07155226Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT07109219Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Menerima peserta
Usia 15 ke atas · Semua jenis kelamin · Diperbarui 10 Jul 2026 · NCT06446661A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- dan 3 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
Menerima peserta
Usia 14 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT03932903Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- University of Chicago Medical Center, Chicago
Menerima pesertaFase 1
Usia 18 hingga 39 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT03571321Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
- University of Chicago Medical Center, Chicago
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Jun 2026 · NCT04747912Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Lurie Children's Hospital-Chicago, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- Saint Jude Midwest Affiliate, Peoria
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT01790152Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
Menerima pesertaFase 1
Usia 13 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT04771572A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 24 Mar 2026 · NCT04988555A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mar 2026 · NCT06207123Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
Menerima pesertaFase 2
Usia 18 hingga 54 · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06918431Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaFase 1
Usia 1 hingga 40 · Semua jenis kelamin · Diperbarui 12 Mar 2026 · NCT05292664Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.